Preclinical Evaluation of Cancer Hazard and Risk of Biopharmaceuticals

Preclinical Safety Evaluation of Biopharmaceuticals: A Science-Based Approach to Facilitating Clinical Trials

Volumn , Issue , 2007, Pages 399-474

  Cavagnaro, Joy A ^a  

^a Access BIO   (United States)

Author keywords

Cancer hazard and risk preclinical evaluation; Host resistance assays and immune function decrease; Preclinical carcinogenicity assessment need

Indexed keywords

EID: 84891551805     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470292549.ch19     Document Type: Chapter

References (68)

1. Pitot HC, Dragan YP. Facts and theories concerning the mechanisms of carcinogenesis . FASEB J 1991; 5: 2280-6.
2. Yuspa SH. Overview of carcinogenesis: past, present and future. Carcinogenesis 2000; 21: 341-4.
3. Contrera JF, Jacobs AC, DeGeorge JJ. Carcinogenicity testing and the evaluation of regulatory requirements for pharmaceuticals. Regul Toxicol Pharmacol 1997 ; 25: 30-45.
4. Jena GB, Kaul CL, Ramarao P. Regulatory requirements and ICH guidelines on carcinogenicity testing of pharmaceuticals: a review on current status. Ind J Pharmacol 2005; 37: 209-22.
5. Williams GM, Iatropoulos MJ. Principles of testing for carcinogenic activity. In Hayes AW, ed. Principles and Methods of Toxicology, 4th ed. Philadelphia: Taylor and Francis, 2001; 1-42.
6. Bucher JR, Portier C. Human carcinogenic risk evaluation. Part V: The National Toxicology Program vision of assessing the human carcinogenic hazard of chemicals . Toxicol Sci 2004; 82: 363-6.
7. Contrera JF, MacLaughlin P, Hall LL, Kier LB. QSAR modeling of carcinogenic risk using discrimiant analysis and topological molecular descriptors. Curr Drug Discov Technol 2005; 2: 55-67.
8. Boorman GA, Maronpot RR, Eustis SL. Rodent carcinogenicity bioassay: past, present and future. Toxicol Pathol 1994; 22 (2): 105-11.
9. Sontag JM, Page NP, Saffiotti U. Guidelines for Carcinogen Bioassay in Small Rodents. National Cancer Institute, NCI-CG-TR-1. DHEW Publ. No. (NIH) 76 - 801. Washington: US G.P.O.
10. Halmes NC, Roberts SM, Tolson JK, Portier CJ. Reevaluating cancer risk estimates for short-term exposure scenarios. Toxicol Sci 2000; 58: 32-42.
11. Crump KS, Howec RB. The multistage model with a time-dependent dose pattern: applications to carcinogenic risk assessment. Risk Anal 1984; 4: 163-76.
12. Weisburger JH, Williams GM. Carcinogen testing: current problems and new approaches. Sci 1981; 214: 401-7.
13. Huff J, Haseman J, Rall D. Scientifi c concepts, value and signifi cance of chemical carcinogenesis studies. Ann Rev Pharmacol Toxicol 1991; 31: 621-52.
14. Benigni R, Zito R. The second National Toxicology Program comparative exercise on the prediction of rodent carcinogenicity: defi nitive results. Muta Res 2004 ; 566: 49-63.
15. Gold LS, Slone TH, Ames BN. What animal cancer tests tell us about human cancer risk? Overview of analyses of the carcinogenic potency database. Drug Metab Rev 1998; 30: 359-404.
16. Jacobs A. Prediction of 2-year carcinogenicity study results for pharmaceutical products: How are we doing? Toxicol Sci 2005; 88: 18-23.
17. Cohen SM. Alternative models for carcinogenicity testing: weight of evidence evaluation across models. Toxicol Pathol 2001; 29: 183-90.
18. MacDonald JS. Human carcinogenic risk evaluation. Part IV: Assessment of human risk of cancer from chemical exposure using a global weight-of-evidence approach. Toxicol Sci 2004; 82: 3-8.
19. Meek ME, Bucher JR, Cohen SM, Dellarco V, Hill RN, Lehman-Mckeeman LD, Longfellow DG, Pastoor T, Seed J, Patton DE. A Framework for human relevance of information on carcinogenic modes of action. Crit Rev Toxicol 2004 ; 33 (6): 591-653.
20. Gottmann E, Kramer S, Pfahringer B, Helma C. Data quality in predictive toxicology: reproducibility of rodent carcinogenicity experiments. Environ Health Persp 2001; 109: 509-14.
21. Cohen SM. Human carcinogenic risk evaluation: an alternative approach to the two-year rodent bioassay. Toxicol Sci 2004; 80: 225-9.
22. IARC. Monographs on the Evaluation of Carcinogenic Risk to Humans. Vol. 50. Pharmaceutical Drugs. International Agency for Research on Cancer, Lyons, France, 1990.
23. Jacobs A, Jacobson-Kram D. Human carcinogenic risk evaluation. Part III. Assessing the cancer hazard and risk in human drug development. Toxicol Sci 2004 ; 81: 260-2.
24. Cohen SM. Infection, cell proliferation and malignancy. In Parsonnet J, Henning S, eds. Microbes and Malignancy: Infection as a Cause of Cancer. New York: Oxford University Press, 1999: 89-106.
25. Hutsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005; 211: 174-87.
26. ICH S1A. International Conference on Harmonization ICH S1A (1995). Need for Carcinogenicity Studies of Pharmaceuticals, 1995. http://www.fda.gov/cder/guidance/index.htm
27. ICH S6. International Conference on Harmonization ICH S6. Preclinical Safety Evaluation of Biotechnology-derived Pharmaceuticals, 1997. http://www.fda.gov/cder/guidance/index.htm
28. Hastings KL. Assessment of immunosuppressant drug carcinogenicity: standard and alternative models. Hum Exp Toxicol. 2000 ; 19: 261-5.
29. ICH Q5D Q5D. Quality of Biotechnological/Biological Products: Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products; Availability, 1998. http://www.fda.gov/cder/guidance/index.htm
30. Hacein - Bey - Abina S , Von Kalle C , Schmidt M , McCormack MP , Wulffraat N , Leboulch P , Lim A , Osborne CS , et al. LMO2 - associated clonal T cell proliferation in two patients after gene therapy for SCID - X1 . Science 2003 ; 302 ( 5644 ): 415 - 9 .
31. Shou Y, Ma Z, Lu T, Sorrentino BP. Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Nat Acad Sci USA 2006; 103 (31): 11730-5.
32. Guidance for Industry. Gene Therapy Clinical Trials-Observing Subjects for Delayed Adverse Events, November 2006. http://www.fda.gov/cber/gdlns/gtclin.pdf
33. Claude JR. Difficulties in conceiving and applying guidelines for the safety evaluation of biotechnology-produced drugs: some examples. Toxicol Lett 1992 ; 64-64: 349-55.
34. Clark J, Leach W, Pippig S, Joshi A, Wu B, House R, Beyer J. Evaluation of a surrogate antibody for preclinical safety tesing of an anti-CD11a monoclonal antibody. Regul Pharmacol 2004; 40: 219-26.
35. Treacy G. Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFalpha monoclonal antibody . Hum Exp Toxicol 2000; 19: 226-8.
36. Cavagnaro JA, Spindler P. Methods for predicting tumorigenicity of immunomodulatory pharmaceuticals. Hum Exp Toxicol 2000; 19: 213-5.
37. Melnick RL, Kohn MC, Portier CJ. Implications for risk assessment of suggested nongenotoxic mechanisms of chemical carcinogenesis. Environ Health Persp 1996; 104 (Suppl 1): 123-34.
38. Lima BS, Van der Laan JW. Mechanisms of nongenotoxic carcinogenesis and assessment of the human hazard. Regul Toxicol Pharmacol 2000; 32: 135-43.
39. Van Oosterhout JP, Van der Laan JW, De Waal EJ, Olejniczak K, Hilgenfeld M, Schmidt V, et al. The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe. Regul Toxicol Pharmacol 1997; 25: 6-17.
40. ICH S1B. International Conference on Harmonization ICH S1B. Testing for Carcinogenicity of Pharmaceuticals, 1997. http://www.fda.gov/cder/guidance/index.htm
41. Cohen SM, Robinson D, MacDonald J. Alternative models for carcinogenicity testing. Toxicol Sci. 2001 ; 64: 14-19.
42. Rosenblum IY, Dayan AD. Carcinogenicity testing of IL-10: principles and practicalities . Hum Exp Toxicol 2002; 21: 347-58.
43. Contrera JF, DeGeorge JJ. In vivo transgenic biossays and assessment of the carcinogenic potential of pharmaceuticals. Environ Health Persp 1998; 106: 71-80.
44. Tenant RW, Spalding J, French JE. Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. Mutat Res 1999; 265: 119-27.
45. Gulzeian D, Jacobson-Kram D, McCullough CB, Olson H, Recio L, Robinson D, Storer R, Tennant R, Ward JM, Neumann DA. Use of transgenic animals for carcinogenicity testing: considerations and implications for risk assessment. Toxicol Pathol 2000; 28: 482-99.
46. Popp JA. Criteria for evaluation of studies in transgenic models. Toxicol Pathol 2001; 29: 20-3.
47. Ashby J. Expectations for transgenic rodent cancer bioassay models. Toxicol Pathol 2001; 29: 177-82.
48. MacDonald J, French JE, Gerson RJ, Goodman J, Inoue T, Jacobs A, Kasper P, Keller D, Lavin A, Long G, et al. The utility of genetically modifi ed mouse assays for identifying human carcinogens: a basic understanding and path forward. Toxicol Sci 2004; 77: 188-94.
49. Flammang TJ, Von Tungeln LS, Kadlubar FF, Fu PP. Neonatal mouse assay for tumorigenicity: alternative to the chronic rodent bioassay. Regul Toxicol Pharmcol 1997; 26: 230-40.
50. Omen GS. Assessment of human cancer risk: challenges for alternative approaches. Toxicol Pathol 2001; 29: 5-12.
51. Goodman JI. A perspective on current and future uses of alternative models for carcinogenicity testing. Toxicol Pathol 2001; 29: 173-6.
52. Mauthe RJ, Gibson DP, Bunch RT, Custer L. The Syrian hamster embryo (SHE) cell transformation assay: review of the methods and results. Toxicol Pathol 2001 ; 29 (Suppl):138-46.
53. Brown DC, Gatter KC. Ki67 protein: the immaculate deception? Histopathology 2002; 40: 2-11.
54. Wierda D. Can host resistance assays be used to evaluate the immunotoxicity of pharmaceuticals? Hum Exp Toxicol 2000; 19: 244-5.
55. Luster MI, et al. Risk assessment in immunotoxicology. II. Relationships between immune and host resistance tests. Fund App Toxicol 1993; 21: 71-82.
56. Bugelski PJ, Herzyk DJ, Rehm S, Harmsen AG, Gore EV, Williams DM, Maleeff BE, Badger AM, Truneh A, O'Brien SR, Macia RA, Wier PJ, Morgan DG, Hart TK. Preclinical development of Keliximab, a primatized anti-CD4 monoclonal antibody, in human transgenic CD4 mice: characterization of the model and safety studies. Hum Exp Toxicol 2000; 19: 230-43.
57. FDA Pharmacology/Toxicology review (anakinra) Kineret. http://www.fda.gov/cder/foi/nda/2001/103950-0_Kineret_Pharmr.PDF12
58. Sinclair AM , Todd MD , Forsythe MD , Knox SJ , Elliott S , Begley CG . Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis - stimulating agents in cancer patients . Cancer 2007 ; 110: 477-88.
59. EPAR Kineret. http://www.emea.europa.eu/humandocs/Humans/EPAR/kineret/ kineret.htm12
60. Watanabe S , Tsunematsu Y , Komiyama A , Fujimoto J . Leukemia in patients treated with growth hormone (Letter) . Lancet 1988 ; 1: 1159-60 .
61. Allen DB. Safety of human growth hormone therapy: current topics. J Pedia 1996 ; 128: S8-13.
62. Nishi Y , Tanaka T , Takano K , Fujieda K , Igarashi Y , Hanew K , Hirano T , Yokoya S , Tachibana K , Saito T , Watanabe S . Recent Status in the Occurrence of Leukemia in Growth Hormone - Treated Patients in Japan . J Clin Endocrinol Metab 1999 ; 84: 1961 - 5 .
63. Farris GM, Miller GK, Wollenberg GK, Molon-Noblot S, Chan C, Prahalada S. Recombinant rat and mouse growth hormones: risk assessment of carcinogenic potential in 2-year bioassays in rats and mice. Toxicol Sci 2007; 97: 548-61.
64. Points to Consider on the Non-clinical Assessment of the Carcinogenic Potential of Insulin Analogues (CPMP/SWP/372/01), November 2001.
65. Jenkins PJ, Besser GM, Farclough PD. Colorectal neoplasia in acromegaly. Gut 1999; 44: 585-7.
66. Guidance for Industry. Development of Parathyroid Hormone for the Prevention and Treatment of Osteoporosis, May 2000.
67. Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocrine Rev 2005; 26: 688-703.
68. EPAR Regranex. http://www.emea.europa.eu/humandocs/PDFs/EPAR/Regranex/028799en6.pdf